Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Yahoo! Finance
company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024 , Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency. On May 30, 2024 , the Former Parent completed the transaction, pursuant to which (i) all assets and liabilities primarily related to INBRX-101 (the "101 Business"), were transferred to Aventis Inc. (the "Acquirer"), a wholly-owned subsidiary of Sanofi S.A. ("Sanofi"); and (ii) by way of a pre-closing reorganization (the "Separation"), the Company acquired the assets and liabilities and corporate infrastructure associated
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx: The Biotech Spinoff Poised For Big Gains [Forbes]Forbes
- Inhibrx gains after insider purchases from CEO [Seeking Alpha]Seeking Alpha
- Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsPR Newswire
- ISCG: Soft Quality, Elevated Volatility, Sluggish Performance [Seeking Alpha]Seeking Alpha
- Inhibrx, Inc. (NASDAQ: INBX) is now covered by analysts at JMP Securities. They set a "market perform" rating on the stock.MarketBeat
INBX
Earnings
- 2/28/24 - Miss
INBX
Sec Filings
- 9/16/24 - Form 4
- 9/12/24 - Form 4
- 9/10/24 - Form 4
- INBX's page on the SEC website